Progress of immunotherapy aiming at preserving residual beta cells of islet
10.3760/cma.j.issn.1673-4408.2010.02.026
- VernacularTitle:免疫药物治疗胰岛残存胰岛β细胞研究进展
- Author:
Ting WANG
;
Weixun HE
;
Guanghua ZHU
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus,type 1;
Immunosuppressive agents;
Insulin-secreting cells
- From:
International Journal of Pediatrics
2010;37(2):190-192
- CountryChina
- Language:Chinese
-
Abstract:
As patients with type 1 diabetes,both the function and number of their beta cells decreased.Despite treating with insulin in early stage,it can't avoid the occurrence of serious complications or death.However,Immunotherapy,different from the previous replacement therapy,emphasizes re-balance between affected T cells and immune regulative effect,suppresses autoimmune reaction,and strengthens the tolerance of beta cells of islet to it.At present,a variety of immune medicines have already been approved for the treatment of type 1 diabetes,such as anti-CD3 monoclonal antibody,GAD-alum,etc.
